Join to View Full Profile
194 Howard St.New London, CT 06320
Phone+1 860-444-3366
Dr. Krasner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 1991 - 1994- Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991
Northwestern University The Feinberg School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2021 - 2027
CT State Medical License 2000 - 2018
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification Horizon Ambulatory Care, McKesson, 2013, 2016-2017
- CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2016-2017
- CMS Meaningful Use Stage Stage 2 Certification Horizon Ambulatory Care™, McKesson, 2013, 2016-2017
Publications & Presentations
PubMed
- 24 citationsDevelopment of Stable Liquid Glucagon Formulations for Use in Artificial PancreasRoderike Pohl, Ming Li, Alan Krasner, Errol De Souza
Journal of Diabetes Science and Technology. 2015-01-01 - 32 citationsA Review of a Family of Ultra-Rapid-Acting Insulins: Formulation Development:Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser
Journal of Diabetes Science and Technology. 2012-07-01 - 7 citationsPostprandial Vascular Effects of VIAject Compared With Insulin Lispro and Regular Human Insulin in Patients With Type 2 DiabetesThomas Forst, Andreas Pfützner, Frank Flacke, Alan Krasner, C. Hohberg
Diabetes Care. 2010-01-01
Press Mentions
Crinetics Pharma Reports Positive Results from Phase 2 Trial of Atumelnant in Congenital Adrenal HyperplasiaJanuary 13th, 2025- Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES CongressNovember 8th, 2021
- $-0.40 EPS Expected for Crinetics Pharmaceuticals, Inc. (CRNX)December 14th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
